Synergistic effect of clinically available β lactamases inhibitors on cefiderocol activity against carbapenemase producing Gram negative organisms


https://doi.org/10.4081/mm.2023.11367
Vol. 38 No. 1 (2023)
Published: 11 April 2023
Abstract Views: 489
PDF: 152
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • G. Bianco Microbiology and Virology Unit , University Hospital Città della Salute e della Scienza di Torino, Turin; Department of Public Health and Paediatrics , University of Turin, Italy.
  • S. Comini Microbiology and Virology Unit , University Hospital Città della Salute e della Scienza di Torino, Turin; Department of Public Health and Paediatrics , University of Turin, Italy.
  • P. Gaibani Operative Unit of Microbiology , IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy.
  • M. Boattini Microbiology and Virology Unit , University Hospital Città della Salute e della Scienza di Torino, Turin; Department of Public Health and Paediatrics , University of Turin, Italy.
  • G. Banche Department of Public Health and Paediatrics , University of Turin, Italy.
  • C. Costa Microbiology and Virology Unit , University Hospital Città della Salute e della Scienza di Torino, Turin; Department of Public Health and Paediatrics , University of Turin, Italy.
  • P. Nordmann Medical and Molecular Microbiology , Faculty of Science and Medicine, University of Fribourg, Fribourg; National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg, Switzerland.
  • R. Cavallo Microbiology and Virology Unit , University Hospital Città della Salute e della Scienza di Torino, Turin; Department of Public Health and Paediatrics , University of Turin, Italy.

Not available.


Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, et al In vitro activity of cefiderocol a siderophore

cephalosporin, against a recent collection of clinically relevant carbapenem non susceptible Gram negative bacilli, including

serine carbapenemase and metallo β lactamase producing isolates (SIDERO WT 2014 Study) Int J Antimicrob Agents 2019;53(177):84 DOI: https://doi.org/10.1016/j.ijantimicag.2018.10.007

Karakonstantis S, Rousaki M, Kritsotakis EI Cefiderocol Systematic Review of Mechanisms of Resistance, Heteroresistance and In

Vivo Emergence of Resistance Antibiotics 2022;11:723. DOI: https://doi.org/10.3390/antibiotics11060723

The European Committee on Antimicrobial Susceptibility Testing Guidance document on broth microdilution testing of

cefiderocol 2020 Available at: http :://www eucast org

Doern CD When does 2 plus 2 equal 5 A review of antimicrobial synergy testing J Clin Microbiol 2014;52(4124):8. DOI: https://doi.org/10.1128/JCM.01121-14

NCCLS 1999 Methods for determining bactericidal activity of antimicrobial agents approved guideline Document M 26 A

National Committee for Clinical Laboratory Standards, Wayne, PA

Bianco, G., Comini, S., Gaibani, P., Boattini, M., Banche, G., Costa, C., Nordmann, P., & Cavallo, R. (2023). Synergistic effect of clinically available β lactamases inhibitors on cefiderocol activity against carbapenemase producing Gram negative organisms. Microbiologia Medica, 38(1). https://doi.org/10.4081/mm.2023.11367

Copyright (c) 2023 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC